Karen Toledo-Stuardo, Nicolás Fehring, Homero Gómez-Velasco, R. Sierpe, D. Guerra, Douglas J. Matthies, Yuneisy Guerra, Fabiola González-Herrera, Mauricio González, Ivo Campos, Samantha Tello, María José Garrido, Gonzalo Vásquez, Jose Rodríguez-Siza, M. Vergara, Carolina H. Ribeiro, Gerald Zapata-Torres, S. Bollo, E. García-Hernández, Denis Fuentealba, N. A. Valdez-Cruz, Claudia Altamirano, Maria Carmen Molina
2026.2.1Biotechnology Reports
tlooto Summary
Combined biophysical, in silico, and cellular data support the wild-type scFv as a promising therapeutic candidate.
Abstract
Highlights • Three label-free methods and ELISA were compared to assess scFv–MICA binding affinity for therapeutic candidate selection.• Surface plasmon resonance (SPR) yielded the most precise and discriminative affinity measurements of the scFv variants.• The wild-type scFv showed superior binding, stability, and functionality compared to the Beta mutant.• Combined biophysical, in silico, and cellular data support the wild-type scFv as a promising therapeutic candidate.
Citation format
TOLEDO-STUARDO, Karen, et al. Comparative analysis of anti-mica scfv affinities: Insights from three label-free biophysical methods and biological validation. Biotechnology Reports, 2026, 50: e00955.